Clinical trials: Mosquito-Borne Diseases
Vivax Malaria
Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)
In Southeast Asia, Plasmodium vivax (Pv) infection reaches 50-80% and bears a greater burden of disease than Plasmodium falciparum (Pf).
- Trial name
- NCT01640574
- Testing
- Dihydroartemisinin-Piperaquine, Chloroquine
- Where
- Thailand
- Volunteers
- 680 people
- Sponsor
- University of Oxford
Falciparum Parasitaemia
An Evaluation of Weekly Tafenoquine
This was a placebo controlled, randomised, double-blind, double-dummy study of the efficacy of weekly tafenoquine compared with weekly mefloquine or placebo in the chemosuppression of P.
- Trial name
- NCT02488980
- Testing
- Tafenoquine, Mefloquine
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
LLIN Evaluation in Uganda Project (LLINEUP3)
In Uganda, the National Malaria Control Division (NMCD) and implementing partners are planning to deliver long-lasting insecticidal nets (LLINs) nationwide, through a mass distribution campaign in 2023.
- Trial name
- NCT05950191
- Testing
- long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual), long lasting insecticidal nets with PBO-pyrethroid (PermaNet), Social Behavior Change Communication
- Where
- Uganda
- Volunteers
- 215,903 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Advanced Ovarian Cancer
Plasmodium Immunotherapy for Advanced Ovarian Cancer
The main purpose of this study is to evaluate the safety and effectiveness of Plasmodium immunotherapy in the treatment of advanced ovarian cancer. This study plans to enroll 30 patients with advanced ovarian cancer.
- Trial name
- NCT05924776
- Testing
- Plasmodium immunotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.
Dengue Disease, Dengue Fever
Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease
The purpose of this study is to determine whether a new investigational dengue vaccine is safe, well-tolerated, and to see if an immune response against dengue disease will be generated.
- Trial name
- TVDV (NCT01502358)
- Testing
- Tetravalent Dengue Vaccine (TVDV), Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose), Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Microcephaly, Mental Retardation
Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
This prospective cohort study will determine the natural history of fetal exposure to Zika virus (ZIKV) and its effects on the fetus and newborn with emphasis on neurodevelopment outcome.
- Trial name
- ZENI (NCT02943304)
- Testing
- Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV
- Where
- Colombia
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- Universidad Industrial de Santander
Weight Loss, Weight Gain
Effect of Ready to Use Therapeutic Food (RUTF) Supplement After an Episode of Malaria Falciparum on Weight
The primary objective of this study is to determine to what extent provision with RUTF will promote catch up growth in children following an acute uncomplicated episode of P. falciparum malaria.
- Conditions
- Weight Loss, Weight Gain, Convalescence, Malaria
- Trial name
- NCT00819858
- Testing
- RUTF (Plumpynut®)
- Where
- Republic of the Congo
- Volunteers
- 180 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Treatment of Acute Zika Virus Infection
Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans
Zika virus (ZIKV) infection is a new emerging arbovirus disease, caused by the same vector that transmits Dengue virus, Aedes aegypti.
- Trial name
- NCT03443830
- Testing
- Tyzivumab
- Where
- Singapore
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tychan Pte Ltd.
Malaria
Ethiopia Malaria Therapeutic Efficacy Study
In this stdy, patients aged above 6 months with symptomatic malaria presenting to health centers will be enrolled for treatment with artemether-lumefantrine for P.
- Trial name
- NCT01052584
- Testing
- Chloroquine- P. vivax, Artemether-Lumefantrine: P. vivax, Artemether-lumefantrine: P. falciparum
- Where
- 2 sites in Ethiopia
- Volunteers
- 354 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria
Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)
The purpose of this study is to evaluate the tolerability and safety of increasing doses of primaquine in combination with artemether-lumefantrine in G6PD deficient males with an asymptomatic P. falciparum malaria infection.
- Trial name
- NCT02174900
- Testing
- Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine, Artemether-Lumefantrine (AL) combination, Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
- Where
- Burkina Faso
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa
The primary objective is to confirm the hypothesis that azithromycin used in combination with chloroquine is non-inferior to artemether- Lumefantrine for the treatment of symptomatic, uncomplicated malaria due to P.
- Trial name
- NCT00677833
- Testing
- Azithromycin plus Chloroquine, Artemether-lumefantrine
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 361 people
- Sponsor
- Pfizer
Japanese Encephalitis
Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine
The objective of this study is to measured the Geometric mean titer (GMT) of Japanese Encephalitis neutralizing antibody and proportion of seroprotection among the children who received a booster dose of JE-CV after the first…
- Trial name
- NCT02602652
- Testing
- a live attenuated chimeric JE vaccine
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Malaria,Falciparum, Morality
An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine
This is an observational case-control study to assess the effectiveness of the R21/Matrix-M vaccine against severe malaria, clinical malaria (in high transmission perennial areas), and to assess if the R21 vaccine recipients are…
- Trial name
- NCT07009847
- Testing
- Case control study of clinical malaria, Case control study of severe malaria, Case control study of death (all cause)
- Where
- 5 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 2,308 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Malaria
A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults
The purpose of this study is to determine whether 2 investigational malaria vaccines are safe as well as protective against malaria in adults living in the United States
- Trial name
- NCT00385047
- Testing
- Group A FMP2.1/AS01B, Group B FMP2.1/AS02A
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)
SB-252263 (Tafenoquine, TQ) is an 8-aminoquinoline (8-AQ) antimalarial drug being developed by GlaxoSmithKline (GSK), the U.S. Army Medical Research and Materiel Command (USAMRMC) and Medicines for Malaria Venture (MMV).
- Trial name
- NCT01205178
- Testing
- Chloroquine, Primaquine, Tafenoquine
- Where
- 2 sites in Thailand
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Falciparum, Malaria, Vivax
A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia.
The primary aim of the comparative trial is to assess the relative safety and efficacy of two artemisinin containing regimens: amodiaquine plus artesunate (AAQ) and artekin both administered once daily for 3 days.
- Trial name
- NCT00157885
- Testing
- Amodiaquine plus artesunate; Artekin
- Where
- Indonesia
- Volunteers
- 400 people
- Sponsor
- Menzies School of Health Research
Malaria
Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects
This was a randomized, subject and investigator-blinded, placebo-controlled, single and multiple ascending intravenous (iv) dose study in healthy subjects to assess the safety and tolerability of KAE609 given in the vein.
- Trial name
- NCT04321252
- Testing
- KAE609
- Where
- Belgium
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Drug Resistance, Plasmodium Falciparum Malaria
Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar
Efficacy and safety of the artemisinin combination therapy (ACT) in uncomplicated falciparum malaria patients in Myanmar and artemisinin molecular markers analysis
- Trial name
- NCT02792816
- Testing
- First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)
- Where
- Burma
- Volunteers
- 550 people
- Sponsor
- Department of Medical Research, Lower Myanmar
Malaria
Malaria Prevalence Around Maferinyah, Guinea
Background: Many women in Sub-Saharan Africa get malaria while they are pregnant. Plasmodium falciparum is a parasite that can cause malaria. Placental malaria (PM) caused by P.
- Trial name
- NCT04105855
- Where
- Guinea
- Volunteers
- 3,392 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali
This study tested the safety of a new malaria vaccine in adults in Mali, West Africa, and measured the ability of the vaccine to stimulate antibodies directed against the malaria protein that the vaccine is based on.
- Trial name
- NCT00308061
- Testing
- FMP1/AS02A, Imovax Rabies Vaccine
- Where
- Mali
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.